anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This observational group will include patients who are completing an exercise-based cardiac rehabilitation program in line with standard care but are not part of the randomized exercise protocol groups (HIIT or MICT). Participants in this group will be combined with HIIT and MICT (as exercise-based cardiac rehabilitation group) for Aims 1b and 2b.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to radiation diagnostics, urology and oncology, can be used for diagnostics of prostate. Perfusion computer tomography of prostate is performed. First, performing scanning in native mode. Upper limit of scanning passes along the upper contour of wings of iliac bones, the lower border – along the lower outline of ischial tuberosity. Then, on the obtained native images, sections are marked for subsequent perfusion scanning of the prostate: the initial scanning edge corresponds to a prostate base-level cut with overlapping of seminal vesicles, end section – to level of an apex of a gland. Volume of the contrast agent is calculated on basis of 0.3 g of iodine per 1 kg of the patient's weight. To construct perfusion maps, starting points are chosen – ellipse ROI: first point – to large arterial vessel, second – to prostate tissue. After that, calculation is performed in automatic mode with subsequent construction of functional maps. Calcificate, metal fragments and gas are not included in the zone of interest. Applied ellipse should not extend beyond the contrasted lumen of a vessel or tissue of the gland. Thereafter, on the functional maps obtained in the central and peripheral zones, at the level of the apex, base and in middle 1/3 gland, the regional blood flow values are determined on both sides: the volume of the regional blood flow (Blood Volume – BV), mean time of passage of blood (Mean Transit Time (MTT), rate of regional blood flow (Blood Flow – BF). At BF 27.96±6.3 ml/100 g/min, BV 3.51±1.0 ml/100 g and MTT 1.4±0.6 s diagnose prostate adenoma. At BF 52.05±9.14 ml/100 g/min, BV 8.4±0.74 ml/100 g and MTT 14.0±0.5 s is diagnosed with prostate adenocarcinoma. Nonionic iodine-containing radiopaque agents with active substance concentration of 350 or 370 mg/ml can be used.EFFECT: method provides higher accuracy of examination, possibility of its carrying out in the presence of contraindications to MRI by differentiation of new growths of prostate when calculating BV, MTT and BF values for adenoma and adenocarcinoma of prostate.1 cl, 8 dwg, 2 ex
Increasing evidence suggests that cannabinoid receptor 2 (CB2R) serves as a promising anti-inflammatory target. While inflammation is known to play crucial roles in the pathogenesis of epilepsy, the involvement of CB2R in epilepsy remains unclear. This study aimed to investigate the effects of a CB2R agonist, AM1241, on epileptic seizures and depressive-like behaviors in a mouse model of chronic epilepsy induced by pilocarpine. A chronic epilepsy mouse model was established by intraperitoneal administration of pilocarpine. The endogenous cannabinoid system (eCBs) in the hippocampus was examined after status epilepticus (SE). Animals were then treated with AM1241 and compared with a vehicle-treated control group. Additionally, the role of the AMPK/NLRP3 signaling pathway was explored using the selective AMPK inhibitor dorsomorphin. Following SE, CB2R expression increased significantly in hippocampal microglia. Administration of AM1241 significantly reduced seizure frequency, immobility time in the tail suspension test, and neuronal loss in the hippocampus. In addition, AM1241 treatment attenuated microglial activation, inhibited pro-inflammatory polarization of microglia, and suppressed NLRP3 inflammasome activation in the hippocampus after SE. Further, the therapeutic effects of AM1241 were abolished by the AMPK inhibitor dorsomorphin. Our findings suggest that CB2R agonist AM1241 may alleviate epileptic seizures and its associated depression by inhibiting neuroinflammation through the AMPK/NLRP3 signaling pathway. These results provide insight into a novel therapeutic approach for epilepsy.
Before subcutaneous injection, 26G sterile disposable needles will be kept in the cooling compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
BACKGROUND: Chronic low back pain (CLBP) is a significant problem affecting millions of people worldwide. Three widely implemented psychological techniques used for CLBP management are cognitive therapy (CT), mindfulness meditation (MM), and behavioral activation (BA). This study aimed to evaluate the relative immediate (pre- to post-treatment) and longer term (pre-treatment to 3- and 6-month follow-ups) effects of group, videoconference-delivered CT, BA, and MM for CLBP.
METHODS: This is a secondary analysis of a three-arm, randomized clinical trial comparing the effects of three active treatments-CT, BA, and MM-with no inert control condition. Participants were N = 302 adults with CLBP, who were randomized to condition. The primary outcome was pain interference, and other secondary outcomes were also examined. The primary study end-point was post-treatment. Intent-to-treat analyses were undertaken for each time point, with the means of the changes in outcomes compared among the three groups using an analysis of variance (ANOVA). Effect sizes and confidence intervals are also reported.
RESULTS: Medium-to-large effect size reductions in pain interference were found within BA, CT, and MM (ds from - .71 to - 1.00), with gains maintained at both follow-up time points. Effect sizes were generally small to medium for secondary outcomes for all three conditions (ds from - .20 to - .71). No significant between-group differences in means or changes in outcomes were found at any time point, except for change in sleep disturbance from pre- to post-treatment, improving more in BA than MM (d =  - .49).
CONCLUSIONS: The findings from this trial, one of the largest telehealth trials of psychological treatments to date, critically determined that group, videoconference-delivered CT, BA, and MM are effective for CLBP and can be implemented in clinical practice to improve treatment access. The pattern of results demonstrated similar improvements across treatments and outcome domains, with effect sizes consistent with those observed in prior research testing in-person delivered and multi-modal psychological pain treatments. Thus, internet treatment delivery represents a tool to scale up access to evidence-based chronic pain treatments and to overcome widespread disparities in healthcare.
TRIAL REGISTRATION: Clinicaltrials.gov, NCT03687762.
Compared with transcription and translation, protein degradation machineries can act faster and be targeted to different subcellular compartments, enabling immediate regulation of signaling events. It is therefore not surprising that proteolysis has been used extensively to control homeostasis of key regulators in different biological processes and pathways. Over the past decades, numerous studies have shown that proteolysis, where proteins are broken down to peptides or amino acids through ubiquitin-mediated degradation systems and proteases, is a key regulatory mechanism to control plant immunity output. Here, we briefly summarize the roles various proteases play during defence activation, focusing on recent findings. We also update the latest progress of ubiquitin-mediated degradation systems in modulating immunity by targeting plant membrane-localized pattern recognition receptors, intracellular nucleotide-binding domain leucine-rich repeat receptors, and downstream signaling components. Additionally, we highlight recent studies showcasing the importance of proteolysis in maintaining broad-spectrum resistance without obvious yield reduction, opening new directions for engineering elite crops that are resistant to a wide range of pathogens with high yield.
Subjects received chemotherapy in 28-day cycles. Subjects on Low-Dose Cytarabine (LoDAC) received 10 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10\~14 days. Subjects on azacitidine received 75 mg/m\^2 daily by SC for 7 days. Subjects on decitabine received 20 mg/m\^2 daily by IV injection for 5 days. Subjects on LoDAC or azacitidine or decitabine treatment continued until they met discontinuation criteria. Subjects on Ara-C±IDA chemotherapy received cytarabine 1\~3 g/m\^2 daily by IV for 3 days and idarubicin 10 mg/m\^2 daily by IV for 3 days. Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m\^2 daily by SC for 6 days (days 1-6), fludarabine 30 mg/m\^2 daily by IV for 5 days (days 2-6), cytarabine 1\~2 g/m\^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m\^2 daily by IV for 3 days (days 2-4). Subjects receiving Ara-C±IDA or FLAG-IDA received 1 cycle of therapy and were assessed for response on day 28+/-2 days.
PURPOSE:An antilipemic agent especially capable of being administered safely for a long period, containing an extract of stalk and skin of sweet potato comprising straight-chain aliphatic aldehyde homologues as main components. CONSTITUTION:A fat-soluble substance showing a gas chromatography chart shown by the figure, comprising straight-chain aliphatic aldehyde homologues shown by the formula I , formula II and formula III as main components, is extracted from stalk and skin of sweet potato with an organic solvent (e.g., benzene, etc.), and isolated by silica gel chromatography. Sweet potato harvested in January is preferable as the sweet potato, and the yield is high when ripened part of stalk near to the root is used. The extract of stalk and skin of sweet potato has antilipemic action, especially lowering action on serum cholesterol, and is useful as an antilipemic agent. It can be administered by any method, and a dose of 50-1,000mg/day/person may be medicated every day in the case of oral administration.
Despite efforts in recent years, including in policy and research, to address health disparities in the United States, many of those disparities continue to fester in marginalized racial/ethnic populations. Understanding sleep health disparities is critical in understanding the health and wellness of these groups. Using obstructive sleep apnea (OSA) in Black populations as a focus, this paper presents the role of race and ethnicity in the clinical understanding of sleep health-related issues by medical practitioners and the implications of the lack of clear policies or best practices to guide medical practitioners' attempts to meet sleep-related needs of marginalized racial/ethnic populations. Furthermore, the knowledge gap may be further complicated by the poor understanding and integration of existing evidence with the many, complex, sleep-associated co-morbidities. Policymaking in this area ought to be based on the ethical implications of disparate sleep-related health outcomes by race and ethnicity. So, we conclude by offering recommendations for developing ethically sound policies for addressing sleep problems in marginalized racial and ethnic populations.
Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
PROBLEM TO BE SOLVED: To obtain the subject new compound for inhibiting the proliferation of tumor cell and exhibiting carcinostatic effects. SOLUTION: A compound of formula I (R<1> is H or methyl; R<2> is O or imino) such as a compound of formula II. The compound of formula I is obtained inoculating a strain capable of producing BE-45985s in a nutrient source- containing medium and aerobically growing the strain to give a culture containing BE-45985s. Glucose, maltose, starch, etc., can be used as the nutrient source. Shaking culture and submerged aerated spinner culture are preferable as the culture method in the case of liquid culture. The culture temperature is 18-29 deg.C, the pH of the medium is 4-8 and the culture time is 96-360 hours. The separation and purification is carried out by filtering the culture solution and extracting the prepared cell with an organic solvent such as methanol or acetone.  The crude extract is subjected to water-ethyl acetate partition, ethyl acetate is distilled away and the extract is subjected to reversed phase column chromatography to give the, objective substance.
Long-term treatment of myocardial infarction is challenging despite medical advances. Tissue engineering shows promise for MI repair, but implantation complexity and uncertain outcomes pose obstacles. microRNAs regulate genes involved in apoptosis, angiogenesis, and myocardial contraction, making them valuable for long-term repair. In this study, we find downregulated miR-199a-5p expression in MI. Intramyocardial injection of miR-199a-5p into the infarcted region of male rats revealed its dual protective effects on the heart. Specifically, miR-199a-5p targets AGTR1, diminishing early oxidative damage post-myocardial infarction, and MARK4, which influences long-term myocardial contractility and enhances cardiac function. To deliver miR-199a-5p efficiently and specifically to ischemic myocardial tissue, we use CSTSMLKAC peptide to construct P-MSN/miR199a-5p nanoparticles. Intravenous administration of these nanoparticles reduces myocardial injury and protects cardiac function. Our findings demonstrate the effectiveness of P-MSN/miR199a-5p nanoparticles in repairing MI through enhanced contraction and anti-apoptosis. miR199a-5p holds significant therapeutic potential for long-term repair of myocardial infarction.
We are testing a coping and communication support (CCS) intervention for advanced stage cancer patients and their family caregivers over the period when goals of care may shift, i.e. beginning shortly after diagnosis. This randomized clinical trial is being conducted in two urban tertiary cancer clinics that reach patients and families in low income and diverse underserved populations: the Louis Stokes Cleveland VAMC and MetroHealth Medical Center. Recruitment and randomization are based on patient's diagnosis and age. The patient had to have been diagnosed with a stage IV cancer within a year of enrollment and they must fall into one of two age groups: middle-aged (ages 40-60); or older (61 and older). Patients are stratified by age group and then randomized to usual care or CCS intervention. Family care-givers are randomized along with the patient. Trained clinical nurse specialists with advanced training in mental health serve as CCS practitioners. They are available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise. The primary goal of this project is to examine main effects of the intervention and patient age group interaction effects of the CCS intervention on perspectives and well-being of family caregivers during advanced cancer care and in bereavement.
More and more studies have shown that microRNAs (miRNAs) play an indispensable role in the study of complex diseases in humans. Traditional biological experiments to detect miRNA-disease associations are expensive and time-consuming. Therefore, it is necessary to propose efficient and meaningful computational models to predict miRNA-disease associations. In this study, we aim to propose a miRNA-disease association prediction model based on sparse learning and multilayer random walks (SLMRWMDA). The miRNA-disease association matrix is decomposed and reconstructed by the sparse learning method to obtain richer association information, and at the same time, the initial probability matrix for the random walk with restart algorithm is obtained. The disease similarity network, miRNA similarity network, and miRNA-disease association network are used to construct heterogeneous networks, and the stable probability is obtained based on the topological structure features of diseases and miRNAs through a multilayer random walk algorithm to predict miRNA-disease potential association. The experimental results show that the prediction accuracy of this model is significantly improved compared with the previous related models. We evaluated the model using global leave-one-out cross-validation (global LOOCV) and fivefold cross-validation (5-fold CV). The area under the curve (AUC) value for the LOOCV is 0.9368. The mean AUC value for 5-fold CV is 0.9335 and the variance is 0.0004. In the case study, the results show that SLMRWMDA is effective in inferring the potential association of miRNA-disease.
Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
PURPOSE: This study aimed to investigate the association between weight-adjusted waist index (WWI) and trabecular bone score (TBS) and to assess the ability of WWI to identify individuals with degraded bone microarchitecture (DBMA).
METHODS: This cross-sectional study included participants aged 20 and older from the National Health and Nutrition Examination Survey. Furthermore, WWI was calculated by waist circumference and body weight. In addition, linear regression models were employed to investigate the association between WWI and TBS, while logistic regression models were employed to determine the association between WWI and the risk of DBMA. Finally, the performance of WWI in identifying individuals with DBMA was using the receiver operating characteristic (ROC) curves with area under the ROC curve.
RESULTS: A total of 4,179 participants with a mean age of 49.90 years were included in the final analysis. WWI was negatively associated with TBS and positively associated with an increased risk of DBMA. Furthermore, the associations between WWI and TBS, as well as DBMA risk, were stable regardless of stratification by age, sex, race, or body mass index (BMI). Moreover, WWI achieved good performances in identifying individuals with DBMA or low TBS. In addition, the combination of WWI and BMI showed better performances in identifying individuals with DBMA or low TBS than WWI or BMI alone.
CONCLUSION: WWI established a negative association with TBS and a positive association with the risk of DBMA. Clinicians should be alert to the potential risk of DBMA among individuals with high WWI. Moreover, WWI, alone or in combination with BMI, has the potential to serve as an early screening strategy in identifying individuals with DBMA.
A pretest was conducted with a group of elderly residents from three different nursing homes. Following this, participants watched 360-degree VR videos featuring nature walks, trips, and similar experiences for 10 minutes, once a week, over a period of four weeks. After completing the VR sessions, a posttest was administered. The results will be used to assess the participants' Quality of Life and their Satisfaction with the intervention.
Fifty patients with swellings in the oral and/or maxillofacial region were randomly selected. Any other swellings that were caused by trauma and/or fracture, extended below the neck or patient reluctant to undergo US were excluded from the study. This study was approved by the (Research Ethics Committee) (REC), Faculty of Dentistry, Minia University before starting the research and all the entire patients had signed a standardized informed consent laid down by REC.

A comprehensive questionnaire was used to assess history and through extra-oral \& intra-oral examinations were carried out and recorded on the basis of criteria reported by Das.11 The ultrasonographic investigations were carried using an ultrasound diagnostic modality (LOGIQ- P5) (GE Medical System, Korea) with color Doppler function by using a linear array transducer, operating at a frequency of (7.5-12 MHz). All the examinations were performed over the swellings and also compared to the contra-lateral/normal side whenever needed. (Fig. 1) All sonographic images were interpreted by an expert sonologist (15 years experience) and US features were recorded to extract ultrasonographic guided (USG) diagnosis and patient's swellings were categorized into five groups: inflammatory/infection/abscess swellings (Group I), cystic swellings (Group II), lymph node swellings (Group III), benign swellings (Group IV) and malignant neoplastic swellings (Group V).12 Finally, the included patients were subjected to either fine needle aspiration cytology (FNAC) or surgical intervention for histopathological examination to extract the histopathological diagnosis
PROBLEM TO BE SOLVED: To obtain a composition for cosmetics, pharmaceuticals and/or dermatosis for treating cutaneous erythema of neurogenic origin, especially rosacea and/or discrete erythema by using an antagonist of peptide derived from calcitonin gene. SOLUTION: Antagonist of calcitonin gene-related peptide(CGRP) is preferably used in an amount of 0.0001-5 wt.% based on total weight of the composition. The composition is preferably topically applied. For example, CGRP-8-37, or anti-CGRP antibody can be used as the CGRP. Furthermore, antagonist of other neuropeptide and/or inflammation-mediated antagonist is preferably formulated in the above composition. A substance P receptor antagonist is preferably used as the antagonist of other neuropeptide.
The invention provides a method for serial processing of deer bone. Products such as deer bone powder, deer bone oil, crystalline particles extracted from the deer bone, deer bone collagen particles and the like, are prepared through the processing treatment to the deer bone such as water boiling, separation, freeze drying and the like. The method can extract effective ingredients and keep active substances of marrow not destroyed, greatly improve the efficacy, and avoid the waste caused by single processing at the same time. The products, namely the crystalline particles extracted from the deer bone and the deer bone collagen particles have efficacies of resisting fatigue, improving the immunity and the like. The deer bone powder has functions of supplementing calcium, strengthening tendons and bones, activating blood and supplementing qi, resisting senility and the like. The products have the special effect of comprehensive treatment on osteoporosis, cervical spondylosis, lumbar vertebra disease, arthritis and the like, can promote bone healing to traumatic fracture, and can be fully absorbed and utilized by bone. The deer bone products after the processing can become novel raw materials in the fields such as food, health care products and the like.